Theratechnologies Inc T.TH

NBOC increases their holding by 117 per cent

[scarlet1967]

“As Theratech's decision to focus primarily on its commercial assets is less risky (vs. early-stage oncology clinical trials) and, likely, to yield results in the NTM, NBF considers this update to be positive. However, given expectations of a generally challenging operating/economic environment (i.e., inflation, labor scarcity, potential supply chain disruptions, etc.) the return to profitability will be monitored closely.
Maintain Sector Perform rating and $3.25 target
National Bank of Canada which owns National Bank Financial increased their holding by 117% as of 2022-12-31 despite the fact that their analyst has been very skeptical of the oncology program from the go and due to “challenging environment” is monitoring the commercial assets’ success…
National Bank Of Canada /fi/ reports 117.30% increase in ownership of TH / Theratechnologies Inc - 13F, 13D, 13G Filings - Fintel.io

[scarlet1967]

  "To us, the main question is why continue to invest in the development of such risky assets when time, bandwidth and cash could, perhaps, be invested in other assets with, potentially, better visibility and/or ROI such as, possibly, TH's commercial platform." This is what National bank’s analyst said on December second day after the pause announcement, not very optimistic

[palinc2000]

Clinical trials by definition are risky but some are riskier .Th 1902 falls into that riskier category and THTX decided to improvize itself in oncology  without any  in house expertise at what appeared to the naked eye to be a low cost acquisition but without the funds needed to support the development of the platform .A small biotech primary goal is to survive and not let itself be

[SPCEO1]

Clinical trials are risky as you point out but TH-1902 had some things going for it that should not be overlooked. First, their CMO was actually a cancer researcher at his previous job at Pfizer, so THTX was not completely without experience in the field. Second, he did a lot of pre-clincial work which had impressive results and that gave everyone confidence TH-1902 might have a better than normal

[palinc2000]

You are right in saying that its not over till its over,But you omit the following 1-Katana tried for more than a year to attract suitors probably already involved in oncology and there were no takers except for THTX  2-The takeover price was peanuts and moreover the selling  shareholders will not be getting any royalties  .....So the selling shareholders were satisfied to get a few

[SPCEO1]

Your first three points were made irrelevant by the excellent preclincial data. They were true atthe outset, but once that data was achieved, it was a whole new story for TH-1902. On point 4, Soleus is indeed in the business of taking risk and I am sure they do not expect to get 100% right. But the fact is they know more about getting things right than we do in this space and this was one they

[palinc2000]

I am guessing but imo more than 15 million has been spent by THTX on the Sort Platform incl Katana  acquisition cost....If THTX were to decide to pursue this dream then they should license out to a pharma and recuperate these costs and collect royalties

[realitycheck4u]

This post has been removed in accordance with Community Policy

[palinc2000]

Yep .I agree !!!..you should contact Paul and tell him to hire JMF 

[Trogarzon]

We should take collective action to do something about the value destruction their communication incompetence has brought us.  For christ sake they completly scrapped the company's valuation and they celebrate their joy of working there in Linkedin and Facebook.  Enough is enough.

[realitycheck4u]

This post has been removed in accordance with Community Policy

[palinc2000]

You are so selfish!!

[scarlet1967]

    They have in house scientists with PHD/post doctoral/ M.Sc.etc. degrees and multi decade expertise in Biochemistry / Pharmacology/Medicinal Chemistry/liquid chromatography human metabolomics…  Add to that UQAM team including professor Richard Bliveau. Now they added external scientists to assist with the sub analysis of the human data thus far. Point is even

[Momo25]

Up to now all those scientists you mentioned are wrong and jfm is right. If they have something appealing to show, we'll be very happy to hear from them. We also be very happy to say jfm is wrong. A phase 1a that took close to 2 years with 0 outcome is not something a scientist will be proud of.

[scarlet1967]

I didn't know JFM's hypothesis was ever been proven to be accurate in a trial? Any clinical trial can fail for many reasons that doesn't mean the design is fraud!. How about getting ride of all those folks and put him in charge spending resources on one person's opinion?

[palinc2000]

I hope that is not a reply to my last 2 posts....I was just being sarcastic !!!   

[scarlet1967]

No it's not just to clarify what has been going on the way I see it.